Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study) | Zendy

C Clavel | Zendy; Gilles Peytavin | Zendy; Roland Tubiana | Zendy; Cathia Soulié | Zendy; C. Crenn-Hébert | Zendy; Isabelle Heard | Zendy; François Bissuel | Zendy; Houria Ichou | Zendy; Claudia Ferreira | Zendy; Christine Katlama | Zendy; AnneGeneviève Marcelin | Zendy; Laurent Mandelbrot | Zendy

Open Access

Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)

Author(s) -

C Clavel,

Gilles Peytavin,

Roland Tubiana,

Cathia Soulié,

C. Crenn-Hébert,

Isabelle Heard,

François Bissuel,

Houria Ichou,

Claudia Ferreira,

Christine Katlama,

AnneGeneviève Marcelin,

Laurent Mandelbrot

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01460-10

Subject(s) - raltegravir , diva , regimen , medicine , human immunodeficiency virus (hiv) , pharmacology , virology , antiretroviral therapy , viral load

We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median raltegravir concentrations were 235 ng/ml in BP and 93 ng/ml in CVF, with a CVF/BP ratio of approximately 2.3. This good penetration of raltegravir may contribute to the control of viral replication in the female genital tract.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research